Jalra M 50/500mg Tablet belongs to the therapeutic classification of Antidiabetic Agents. The primary composition for this medicine is Vildagliptin 50 MG, Metformin 500 MG.

Jalra-M 50 mg/500 mg Tablet 15's should not be used in patients with type 1 diabetes or with diabetic ketoacidosis. Some diabetic patients, while taking Jalra-M 50 mg/500 mg Tablet 15's, might develop a rare but serious condition called lactic acidosis. In this condition, there is too much lactic acid accumulated in the blood that can damage the working of your liver and kidney required for the elimination of excess lactic acid from the blood. Before you start taking Jalra-M 50 mg/500 mg Tablet 15's, tell your doctor if you’ve ever had pancreatitis (inflammation of the pancreas), kidney disease, and low vitamin B12 level. Jalra-M 50 mg/500 mg Tablet 15's, when used with insulin, may extremely lower the blood sugar level leading to hypoglycaemia condition, which can be fatal. In this case, your doctor may adjust the dose by lowering the dose of insulin or Jalra-M 50 mg/500 mg Tablet 15's. Prolonged intake of Jalra-M 50 mg/500 mg Tablet 15's may lower your thyroid-stimulating hormone (TSH); hence, an annual check-up of TSH is recommended. In rare cases, you may also develop a serious skin reaction known as bullous pemphigoid that requires immediate medical attention. Tell your doctor if you are going to have a diagnostic test with an injection of dye or X-ray contrast agent. The use of Jalra-M 50 mg/500 mg Tablet 15's should be stopped for a short time before having an X-ray procedure.